35998-04-0 Usage
Uses
Used in Pharmaceutical Industry:
6-Methylgramine is used as a potential therapeutic agent for neurodegenerative diseases such as Alzheimer's due to its ability to inhibit acetylcholinesterase, which helps in maintaining the levels of acetylcholine, a neurotransmitter crucial for cognitive functions.
Used in Neuroprotective Applications:
6-Methylgramine is used as a neuroprotective agent for its potential antioxidant and neuroprotective effects, which may help in reducing oxidative stress and protecting neurons from damage in neurodegenerative conditions.
Used in Research and Development:
6-Methylgramine is used as a subject of research for further exploration of its pharmacological properties and therapeutic potential in treating various diseases and conditions, particularly those related to the nervous system.
Check Digit Verification of cas no
The CAS Registry Mumber 35998-04-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,5,9,9 and 8 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 35998-04:
(7*3)+(6*5)+(5*9)+(4*9)+(3*8)+(2*0)+(1*4)=160
160 % 10 = 0
So 35998-04-0 is a valid CAS Registry Number.
InChI:InChI=1/C12H16N2/c1-9-4-5-11-10(8-14(2)3)7-13-12(11)6-9/h4-7,13H,8H2,1-3H3
35998-04-0Relevant articles and documents
Catalyst-Controlled Regiodivergence in Rearrangements of Indole-Based Onium Ylides
Nair, Vaishnavi N.,Kojasoy, Volga,Laconsay, Croix J.,Kong, Wang Yeuk,Tantillo, Dean J.,Tambar, Uttam K.
supporting information, p. 9016 - 9025 (2021/06/30)
We have developed catalyst-controlled regiodivergent rearrangements of onium-ylides derived from indole substrates. Oxonium ylides formed in situ from substituted indoles selectively undergo [2,3]- and [1,2]-rearrangements in the presence of a rhodium and a copper catalyst, respectively. The combined experimental and density functional theory (DFT) computational studies indicate divergent mechanistic pathways involving a metal-free ylide in the rhodium catalyzed reaction favoring [2,3]-rearrangement, and a metal-coordinated ion-pair in the copper catalyzed [1,2]-rearrangement that recombines in the solvent-cage. The application of our methodology was demonstrated in the first total synthesis of the indole alkaloid (±)-sorazolon B, which enabled the stereochemical reassignment of the natural product. Further functional group transformations of the rearrangement products to generate valuable synthetic intermediates were also demonstrated.
